Sun Pharma Advanced Research Company

    SPARC
    Pharma
    ₹190.12
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹6,170 Cr

    P/E
    3.77
    Day range
    ₹188.00 – ₹194.45
    52-week range
    ₹108.00 – ₹289.00
    Volume
    6.10 L
    Open
    ₹192.64
    Prev close
    ₹193.24

    Latest results · Q2 FY27(consolidated)Revenue ₹30 Cr+282.1%Profit ₹-24 CrMargin -81.2%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Material exchange filing

      Clarification sought from Sun Pharma Advanced Research Company Ltd · 11 Nov 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 53 / 100

    Factor percentiles

    Value54
    Quality71
    Momentum71
    Low volatility14

    Derived metrics

    Earn. yield
    26.5%
    Graham no.
    ₹223.57
    vs Graham
    +17.6%
    ROE ÷ P/B
    63.7%
    12-1 mom.
    +43.6%
    Return / vol
    0.82
    Magic Formula
    #1
    Piotroski
    4/6
    FCF yield
    -4.2%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Sun Pharma Advanced Research CompanySPARC₹6,170 Cr3.774.35277.1%164.0%-152.0%0.00+275.0%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1h ago

    Headlines about Sun Pharma Advanced Research Company from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    3.8
    Price / Book
    4.28
    ROE (FY26)
    277.1%
    ROCE (latest year)
    164%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹188.42
    Price above
    50-day
    ₹192.66
    Price below
    200-day
    ₹181.45
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +98.8%
    Revenue YoY (Sep 2026)
    +275.0%
    Operating margin
    -152.0%
    Net margin
    -80.0%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -500 Cr0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026-850%0%850%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017 (S)Mar 2019 (S)Mar 2021 (S)Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY16FY17FY18FY19FY20FY23FY24FY26-400%-200%0%200%400%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    -500 Cr0 Cr500 Cr1K Cr1.5K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018 (S)Mar 2020 (S)Mar 2022 (S)Mar 2023Mar 2024Mar 2025Sep 20260x2x4x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales14171713152710881,8534030
    YoY Sales growth—-65-30-39——-43-39-43———
    Expenses1161221101168980627465807476
    Operating Profit-103-106-93-103-74-53-52-66-571,773-34-46
    OPM %-740%-639%-555%-800%-494%-196%-540%-836%-670%96%-85%-152%
    Other Income64200090-1222424
    Interest0111356891280
    Depreciation333333333222
    Profit before tax-100-105-96-107-79-61-52-76-801,761-21-24
    Tax %0%0%0%0%0%-1%0%0%0%0%1%0%
    Net Profit-100-106-96-107-80-60-52-76-801,761-21-24
    EPS in Rs₹-3.07₹-3.26₹-2.96₹-3.31₹-2.45₹-1.84₹-1.60₹-2.34₹-2.48₹54.27₹-0.64₹-0.75

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days2

    -23 days since Mar 2021 (S)

    Inventory Days0

    0 days since Mar 2021 (S)

    Cash Conversion Cycle2

    -23 days since Mar 2021 (S)

    Working Capital Days215

    +483 days since Mar 2021 (S)

    Strengths, risks & growth

    Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. [1]

    Strengths

    • Company has reduced debt.
    • Company is almost debt free.

    Risks

    • Stock is trading at 4.35 times its book value
    • Working capital days have increased from -768 days to 215 days

    Compounded Sales Growth

    10 Years
    —
    5 Years
    —
    3 Years
    +99%
    TTM
    +3141%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    —
    3 Years
    +108%
    TTM
    +717%

    Stock Price CAGR

    10 Years
    -5%
    5 Years
    -6%
    3 Years
    -8%
    1 Year
    +47%

    Return on Equity

    10 Years
    —
    5 Years
    —
    3 Years
    —
    Last Year
    +279%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter65.67%65.67%65.68%65.68%0.00 pp
    FII2.04%2.04%3.90%3.74%-0.16 pp
    DII0.78%0.88%0.09%0.11%+0.02 pp
    Public31.51%31.41%30.34%30.48%+0.14 pp

    Filed with NSE for Sept 2026: promoters 65.67%, public 34.33%

    Analysts & fund holdings

    100%
    100% recommend buy
    1 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E3.8 vs 45.1
    Sector P/B6.03
    Beta1.42

    Who holds the shares, quarter by quarter

    Mutual funds 0.10% (+0.02 pp)
    Sept 25
    Dec 25
    Mar 26
    May 26
    Jun 26
    Sept 26
    • Promoters65.7%
    • Foreign institutions3.8%
    • Mutual funds0.1%
    • Insurance0.0%
    • Other domestic institutions0.0%
    • Retail14.5%
    • Others15.9%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Motilal Oswal Nifty Microcap 250 Index Fund0.07%0.20%-0.01 pp
    Samco Multi Cap Fund0.01%0.30%-0.05 pp
    Groww Nifty Total Market Index Fund0.00%0.01%-0.00 pp
    Bandhan BSE Healthcare Index Fund0.00%0.10%-0.02 pp
    Aditya Birla SL BSE Total Market Index Fund0.00%0.01%+0.01 pp

    Scorecard

    Performance
    Avg
    Valuation
    Avg
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    54.5%
    Downside volatility
    41.7%
    Worst 5% of days
    4.6%
    Average of that tail
    6.0%
    Max drawdown (1Y)
    38.1%
    Below its peak
    31.5%

    Against the market

    Beta vs Nifty 50
    1.65
    Correlation
    0.41
    Relative strength (3M)
    -7.5%
    ATR (14)
    5.0%

    Return

    Return 1M
    +0.8%
    Return 3M
    -3.7%
    Return 6M
    +17.2%
    Return 1Y
    +44.7%
    vs 200-day average
    +4.8%

    Momentum

    RSI (14)
    47.9
    MACD histogram
    0.95
    Stochastic %K
    39.9
    ADX (14)
    18.1
    +DI / −DI
    26.0 / 24.3
    Money flow index
    83.4

    Participation

    Delivery (20d avg)
    34.8%
    vs its 60-day baseline
    -4.0 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    -0.0%
    52-week position
    48 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — failed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    -₹263 Cr
    FCF yield
    -4.2%
    Cash conversion
    -0.15
    Accruals ratio
    0.825
    Net debt
    -₹0 Cr
    Net debt / equity
    -0.00
    EV / sales
    3.25
    Capex intensity
    1.3%
    Revenue CAGR
    6.8%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Sept 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Sept 2020
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      18 Jul 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      19 Jul 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      27 Jul 2017
      ex-date
    • other
      Not available — not reported in this filing

      Extraordinary General Meeting

      25 May 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Jul 2016
      ex-date
    • rights
      Not available — not reported in this filing

      Rights 5: 116 At Premium Rs 244/- Per Share

      16 Mar 2016
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Jul 2015
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      24 Jul 2014
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      24 Jul 2013
      ex-date
    • rights
      Not available — not reported in this filing

      Rights 1: 7@ Premium Rs 66 Per Share

      23 Aug 2012
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      28 Jul 2011
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      16 Jul 2010
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Aug 2009
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      25 Aug 2008
      ex-date
    • other
      Not available — not reported in this filing

      Agm

      28 Aug 2007
      ex-date

    Company announcements

    Company Update
    Receipt Of No-Objection Letters From The Stock Exchanges For Reclassification Of Promoter Group

    Receipt of No- Objection Letters from the Stock Exchanges for Reclassification of Promoter Group

    Company Update
    Clarification Regarding Increase In Volume

    Response of Clarification sought from BSE Limited

    Company UpdatePrice-sensitive
    Clarification sought from Sun Pharma Advanced Research Company Ltd

    The Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement for Publication of Financial Results

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Monitoring Agency Report for the quarter ended September 30, 2026

    Result
    Financial Results For The Quarter And Half Year Ended September 30, 2026

    Financial Results for the quarter and half year ended September 30, 2026

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026

    Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Confirmation Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018

    Company Update
    Update On Litigation - Intimation Under Regulation 30 Of SEBI (LODR), 2015

    Update on Litigation under regulation 30 of SEBI (LODR), 2015

    Insider Trading / SAST
    Closure of Trading Window

    Intimation regarding Closure of Trading Window

    Company Update
    Filing Of Application For Reclassification With Stock Exchanges

    Filing of Application for Reclassification with Stock Exchanges

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement for Publication of Financials

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of 21st Annual General Meeting of Sun Pharma Advanced Research Company Limited held on August 10, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Monitoring Agency Report for the Quarter ended June 30, 2026

    Result
    Unaudited Financial Results For The Quarter Ended June 30, 2026

    Financial Results

    Filed with BSE (scrip 532872); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Rights issue

      Sun Pharma Advanced Research Company Limited

      22 Mar 2016
      Read on SEBI
    • Rights issue

      Sun Pharma Advanced Research Company Limited.

      21 Sept 2015
      Read on SEBI
    • Rights issue

      Sun Pharma Advanced Research Company Limited

      16 Aug 2012
      Read on SEBI
    • Rights issue

      Sun Pharma Advanced Research Company Limited

      2 Feb 2012
      Read on SEBI

    Documents

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Sun Pharma Advanced Research Company: common questions

    Answered from the figures on this page.

    Sun Pharma Advanced Research Company last traded at ₹190.12 (NSE, as of 18 Nov 2026). The last session moved it down 1.61%.

    Sun Pharma Advanced Research Company is valued at about ₹6,170 crore (NSE, as of 18 Nov 2026).

    Sun Pharma Advanced Research Company trades at a price-to-earnings ratio of 3.77 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Sun Pharma Advanced Research Company has traded between ₹108.00 and ₹289.00 over the past 52 weeks, to 18 Nov 2026. It is currently 45% of the way up that range.

    Sun Pharma Advanced Research Company (SPARC) is classified under Pharma on this site's screener.